ReviewCA: a cancer journal for clinicians2022
Magnetic resonance linear accelerator technology and adaptive radiation therapy: An overview for clinicians.
Review in CA: a cancer journal for clinicians, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 68 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
68 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Manganese-derived biomaterials for tumor diagnosis and therapy.Journal of nanobiotechnology · 2024Pooled it
- Clinical application of MR-Linac in tumor radiotherapy: a systematic review.Radiation oncology (London, England) · 2023Pooled it
- Economic Evaluations of Magnetic Resonance Image-Guided Radiotherapy (MRIgRT): A Systematic Review.International journal of environmental research and public health · 2022Pooled it
- Study of Adaptive Radiotherapy for High-Grade Glioma Based on Interfraction MRI.Cancer medicine · 2026Trial
- Efficacy and safety of MR-guided adaptive simultaneous integrated boost radiotherapy to primary lesions and positive lymph nodes in the neoadjuvant treatment of locally advanced rectal cancer: a randomized controlled phase III trial.Radiation oncology (London, England) · 2024Trial
- ACPSEM guideline: commissioning and quality assurance of Magnetic Resonance Imaging Linear Accelerators.Physical and engineering sciences in medicine · 2026Article
- Article
- Article
- MRI-enhanced online adaptive radiotherapy by virtual integration of a standalone MRI simulator and CBCT-based treatment delivery.Radiation oncology (London, England) · 2026Article
- Dosimetric impact of daily MR-guided adaptive radiotherapy across different anatomical sites.Irish journal of medical science · 2026Article
- Radiomics: Current Applications and Future Directions.MedComm · 2026Review
- A new perspective on radiotherapy in the comprehensive treatment of cancer.Precision radiation oncology · 2026Review
- Improving workflow efficiency during prostate stereotactic body radiotherapy using real-time adaptive planning associated with reduced intra-fractional target motion.Radiation oncology (London, England) · 2026Article
- Synthetic CT imaging for pelvic and abdominal MR-only radiotherapy: Clinical validation on a 1.5T MR-Linac.Journal of applied clinical medical physics · 2026Article
- Strategies for enhancing delivery efficiency on MR-Linac: A dosimetric study and historical plan review.Journal of applied clinical medical physics · 2026Article
- Optical Flow-Guided Analysis of Intrafractional Anatomical Variations in Pancreatic Tumors and Organs at Risk During Magnetic Resonance-Guided Adaptive Radiation Therapy Under Abdominal Compression.Advances in radiation oncology · 2026Article
- Time toxicity in CBCT-guided radiation therapy: A retrospective analysis of unplanned imaging burden across disease sites.Technical innovations & patient support in radiation oncology · 2026Article
- Prospective evaluation of liver cancer volumes on non-contrast 1.5 T MR Linac imaging.Clinical and translational radiation oncology · 2026Article
- Acceptance testing of a 0.35 T MR-Linac: procedures, QA baseline, and system limitations.Journal of applied clinical medical physics · 2026Article
- Low-dose X-ray-activated radiodynamic therapy via a lutetium-coordinated nanoplatform synergizing PARP inhibition and ferroptosis.Journal of nanobiotechnology · 2026Article
8 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Radiation therapy (RT) continues to play an important role in the treatment of cancer. Adaptive RT (ART) is a novel method through which RT treatments are evolving. With the ART approach, computed tomography or magnetic resonance (MR) images are obtained as part of the treatment delivery process. This enables the adaptation of the irradiated volume to account for changes in organ and/or tumor position, movement, size, or shape that may occur over the course of treatment. The advantages and challenges of ART maybe somewhat abstract to oncologists and clinicians outside of the specialty of radiation oncology. ART is positioned to affect many different types of cancer. There is a wide spectrum of hypothesized benefits, from small toxicity improvements to meaningful gains in overall survival. The use and application of this novel technology should be understood by the oncologic community at large, such that it can be appropriately contextualized within the landscape of cancer therapies. Likewise, the need to test these advances is pressing. MR-guided ART (MRgART) is an emerging, extended modality of ART that expands upon and further advances the capabilities of ART. MRgART presents unique opportunities to iteratively improve adaptive image guidance. However, although the MRgART adaptive process advances ART to previously unattained levels, it can be more expensive, time-consuming, and complex. In this review, the authors present an overview for clinicians describing the process of ART and specifically MRgART.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.